Figure 2.
Altered CXCR4 internalization in WHIM1013 lymphocytes. (A) Cell surface expression levels of CXCR4 in CD4+-gated T cells from PBMCs of a healthy subject (control, left panel) or WHIM1013 patient P1 (right panel). CXCR4 levels were assessed using the 12G5 (empty histograms) or isotype control (CTRL, gray histograms) mAb. (B) CXCR4 cell surface expression in CD4+-gated T cells from PBMCs of WHIM1013 patients P1 (▦) and P2 (▪) or healthy subjects (□). *P < .05 and **P < .005 compared with healthy subjects. (C) Time course of CXCL12-promoted CXCR4 endocytosis in CD4+-gated T cells from patients P1 (▦) and P2 (▪) versus healthy subject (□). (D) CXCR4 cell surface expression in A0.01 T cells (left panel) or PBMCs from healthy individuals (right panel) nontransduced (NT) or transduced with the indicated CXCR4 variant receptors. □ indicates +CXCL12; ▪, +PMA. In untreated A0.01 T cells, the geometric MFI of CXCR4wt, CXCR41000, and CXCR41013 receptors were 30, 35, and 28, respectively. Analysis in PBMCs was assessed in CD4+-gated T cells. *P < .05 and **P < .005 compared with CXCR4wt-expressing A0.01 T cells or with NT T lymphocytes. Results, expressed as percentage of untreated cells, are from 3 independent experiments (mean ± SEM) (B,D) or from 1 representative experiment of 2 (C). (E) Cell surface expression of T7-GFP-CXCR4wt in CXCR4wt or CXCR41013 CHO cells either untreated (dot plot, top) or treated with CXCL12 (bottom). □ indicates CXCR4wt; ▪, CXCR41013. In untreated CHO cells, the geometric MFI of CXCR4wt GFP-/gate A), CXCR41013 GFP- (gate B), CXCR4wt GFP+ (gate C), and CXCR41013 GFP+ (gate D) were 47, 57, 63, and 61, respectively. Expression of T7-GFP-CXCR4wt is roughly comparable when coexpressed with CXCR4wt (geometric MFI = 150, gate E) or CXCR41013 (geometric MFI = 130, gate F). Analysis of CXCL12-promoted receptor endocytosis was performed in the cell gates defined earlier in the legend. Results (mean ± SEM) are representative of 2 determinations and are expressed as percentage of untreated cells. (F) Cell surface expression of T7-GFP-CXCR4wt in CD4+-gated T cells from PBMCs of a healthy individual transfected with CXCR4wt or CXCR41013 variant either untreated (dot plot, upper panel) or treated with CXCL12 or PMA (lower panel). □ indicates CXCR4wt; ▪, CXCR41013. In untreated CD4+-gated T cells, the geometric MFI of CXCR4 in gates A, B, C, and D were 195, 210, 620, and 580, respectively. Expression of T7-GFP-CXCR4wt is roughly comparable when coexpressed with CXCR4wt (geometric MFI = 260, gate E) or CXCR41013 (geometric MFI = 220, gate F). Analysis of CXCL12- or PMA-promoted receptor endocytosis was performed in cell gates defined above. Results are from 1 representative experiment of 2 and are expressed as percentage of untreated cells.

Altered CXCR4 internalization in WHIM1013 lymphocytes. (A) Cell surface expression levels of CXCR4 in CD4+-gated T cells from PBMCs of a healthy subject (control, left panel) or WHIM1013 patient P1 (right panel). CXCR4 levels were assessed using the 12G5 (empty histograms) or isotype control (CTRL, gray histograms) mAb. (B) CXCR4 cell surface expression in CD4+-gated T cells from PBMCs of WHIM1013 patients P1 (▦) and P2 (▪) or healthy subjects (□). *P < .05 and **P < .005 compared with healthy subjects. (C) Time course of CXCL12-promoted CXCR4 endocytosis in CD4+-gated T cells from patients P1 (▦) and P2 (▪) versus healthy subject (□). (D) CXCR4 cell surface expression in A0.01 T cells (left panel) or PBMCs from healthy individuals (right panel) nontransduced (NT) or transduced with the indicated CXCR4 variant receptors. □ indicates +CXCL12; ▪, +PMA. In untreated A0.01 T cells, the geometric MFI of CXCR4wt, CXCR41000, and CXCR41013 receptors were 30, 35, and 28, respectively. Analysis in PBMCs was assessed in CD4+-gated T cells. *P < .05 and **P < .005 compared with CXCR4wt-expressing A0.01 T cells or with NT T lymphocytes. Results, expressed as percentage of untreated cells, are from 3 independent experiments (mean ± SEM) (B,D) or from 1 representative experiment of 2 (C). (E) Cell surface expression of T7-GFP-CXCR4wt in CXCR4wt or CXCR41013 CHO cells either untreated (dot plot, top) or treated with CXCL12 (bottom). □ indicates CXCR4wt; ▪, CXCR41013. In untreated CHO cells, the geometric MFI of CXCR4wt GFP-/gate A), CXCR41013 GFP- (gate B), CXCR4wt GFP+ (gate C), and CXCR41013 GFP+ (gate D) were 47, 57, 63, and 61, respectively. Expression of T7-GFP-CXCR4wt is roughly comparable when coexpressed with CXCR4wt (geometric MFI = 150, gate E) or CXCR41013 (geometric MFI = 130, gate F). Analysis of CXCL12-promoted receptor endocytosis was performed in the cell gates defined earlier in the legend. Results (mean ± SEM) are representative of 2 determinations and are expressed as percentage of untreated cells. (F) Cell surface expression of T7-GFP-CXCR4wt in CD4+-gated T cells from PBMCs of a healthy individual transfected with CXCR4wt or CXCR41013 variant either untreated (dot plot, upper panel) or treated with CXCL12 or PMA (lower panel). □ indicates CXCR4wt; ▪, CXCR41013. In untreated CD4+-gated T cells, the geometric MFI of CXCR4 in gates A, B, C, and D were 195, 210, 620, and 580, respectively. Expression of T7-GFP-CXCR4wt is roughly comparable when coexpressed with CXCR4wt (geometric MFI = 260, gate E) or CXCR41013 (geometric MFI = 220, gate F). Analysis of CXCL12- or PMA-promoted receptor endocytosis was performed in cell gates defined above. Results are from 1 representative experiment of 2 and are expressed as percentage of untreated cells.

Close Modal

or Create an Account

Close Modal
Close Modal